Pediatric Portfolio (e.g., NatruSmile™, Karbinal™ ER)
Various (Fluoride Deficiency, Allergies)
ApprovedMarketed (Legacy)
Key Facts
Indication
Various (Fluoride Deficiency, Allergies)
Phase
Approved
Status
Marketed (Legacy)
Company
About Aytu BioScience
Aytu BioPharma is a publicly traded, commercial-stage biopharmaceutical company with a distinct focus on complex CNS conditions, including MDD and ADHD. Its strategy centers on acquiring, in-licensing, and commercializing novel therapeutics, supported by a best-in-class patient access platform, Aytu RxConnect. The company has built a portfolio of FDA-approved products, most notably the recently launched antidepressant EXXUA™ (gepirone), while managing a legacy portfolio of pediatric and other specialty products. Aytu's hybrid model generates revenue from commercial sales to fund operations and strategic growth initiatives.
View full company profile